Black Creek Investment Management Inc. Sells 2,523,681 Shares of Grifols, S.A. $GRFS

Black Creek Investment Management Inc. lessened its position in Grifols, S.A. (NASDAQ:GRFS) by 20.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,045,957 shares of the biotechnology company’s stock after selling 2,523,681 shares during the quarter. Grifols makes up about 4.7% of Black Creek Investment Management Inc.’s investment portfolio, making the stock its 12th largest holding. Black Creek Investment Management Inc. owned about 1.46% of Grifols worth $100,058,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brandes Investment Partners LP boosted its stake in Grifols by 8.9% during the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after acquiring an additional 2,294,113 shares in the last quarter. Vinva Investment Management Ltd bought a new position in shares of Grifols during the second quarter valued at approximately $256,000. New York State Common Retirement Fund lifted its holdings in shares of Grifols by 5.6% during the third quarter. New York State Common Retirement Fund now owns 2,589,406 shares of the biotechnology company’s stock valued at $25,790,000 after purchasing an additional 136,678 shares during the last quarter. AdvisorShares Investments LLC bought a new stake in shares of Grifols in the 3rd quarter worth approximately $1,012,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Grifols by 31.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock worth $24,783,000 after buying an additional 600,118 shares during the last quarter.

Grifols Stock Performance

Shares of GRFS stock opened at $8.64 on Wednesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.51 and a quick ratio of 0.88. Grifols, S.A. has a 1 year low of $6.19 and a 1 year high of $11.14. The firm has a fifty day moving average price of $9.21 and a 200-day moving average price of $9.31.

Analyst Upgrades and Downgrades

GRFS has been the subject of several analyst reports. Wall Street Zen downgraded Grifols from a “strong-buy” rating to a “buy” rating in a report on Saturday. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Four equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Grifols currently has a consensus rating of “Hold” and an average target price of $10.00.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.